CSF sTREM2 correlates with CSF tau in advancing Parkinson’s disease

Abstract

222 Introduction: 565 Participants and Methods: 966 Abstract Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD) and affects 1% of the population above 60 years old. Although PD commonly manifests with motor symptoms, a majority of patients with PD subsequently develop cognitive impairment which often progresses to dementia, a major cause of morbidity and disability. PD is characterized by α -synuclein accumulation that frequently associates with amyloid beta (Aβ) and tau fibrils, the hallmarks of AD neuropathologic changes; this cooccurrence suggests that onset of cognitive decline in PD may be associated with appearance of pathologic Aβ and/or tau. Recent studies have highlighted the appearance of the soluble form of the Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) receptor in CSF during development of AD. Given the known association of microglial activation with advancing PD, we investigated whether CSF and/or plasma sTREM2 increased with progression to PD dementia. We examined 165 participants consisting of 17 cognitively normal elderly, 45 PD patients with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF Aβ and tau levels revealed that CSF sTREM2concentrations were elevated in PD subgroups with abnormal tau, but not Aβ, CSF concentration. These findings indicate that CSF sTREM2 could serve as a surrogate immune biomarker of neuronal injury in PD that is associated with cognitive decline.

Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias

“…Latest research by Edward et al (Wilson et al., 2019) studied sTREM2 CSF and plasma levels during the progression of PD dementia. A total of 165 participants included cognitively normal elderly patients (17 patients), no cognitive disability PD patients (45 patients), moderate cognitive impairment (86 patients), and 17 dementia patients.…”